Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
International Journal of Immunopharmacology
|
April 1, 1992
The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor
R L Bell, P R Young, D Albert, et al.
Shock (Augusta, Ga.)
|
August 1, 1996
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats
D H Albert, G Luo, T J Magoc, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 1, 1991
5-lipoxygenase inhibitory activity of zileuton
G W Carter, P R Young, D H Albert, et al.
Journal of Medicinal Chemistry
|
May 29, 1992
Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists
D E Guinn, J B Summers, H R Heyman, et al.
Journal of Medicinal Chemistry
|
March 1, 1990
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships
J B Summers, K H Kim, H Mazdiyasni, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
August 1, 1997
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats
D H Albert, P Tapang, D W Morgan, et al.
Agents and Actions
|
March 1, 1993
The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor
R L Bell, J Bouska, P R Young, et al.
Journal of Medicinal Chemistry
|
February 28, 1997
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors
T Kolasa, C D Brooks, K E Rodriques, et al.
Journal of Medicinal Chemistry
|
November 1, 1987
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase
J B Summers, B P Gunn, H Mazdiyasni, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
July 1, 1997
Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist
D H Albert, T J Magoc, S D Menacherry, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
International Journal of Immunopharmacology
|
April 1, 1992
The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor
R L Bell, P R Young, D Albert, et al.
Shock (Augusta, Ga.)
|
August 1, 1996
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats
D H Albert, G Luo, T J Magoc, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 1, 1991
5-lipoxygenase inhibitory activity of zileuton
G W Carter, P R Young, D H Albert, et al.
Journal of Medicinal Chemistry
|
May 29, 1992
Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists
D E Guinn, J B Summers, H R Heyman, et al.
Journal of Medicinal Chemistry
|
March 1, 1990
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships
J B Summers, K H Kim, H Mazdiyasni, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
August 1, 1997
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats
D H Albert, P Tapang, D W Morgan, et al.
Agents and Actions
|
March 1, 1993
The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor
R L Bell, J Bouska, P R Young, et al.
Journal of Medicinal Chemistry
|
February 28, 1997
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors
T Kolasa, C D Brooks, K E Rodriques, et al.
Journal of Medicinal Chemistry
|
November 1, 1987
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase
J B Summers, B P Gunn, H Mazdiyasni, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
July 1, 1997
Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist
D H Albert, T J Magoc, S D Menacherry, et al.
Page
of 4